Prosecution Insights
Last updated: April 19, 2026

The Schepens Eye Research Institute, Inc.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
2
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18271250 METHODS AND COMPOSITIONS FOR MODULATING THE INTERACTION BETWEEN ADENO-ASSOCIATED VIRUS (AAV) AND THE AAV RECEPTOR (AAVR) FOR ALTERED BIO-DISTRIBUTION OF AAV HILL, MYRON G 1671 Non-Final OA Jul 07, 2023
18267905 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS OH, TAYLOR V 1625 Non-Final OA Jun 16, 2023
18256277 COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY HELM, CARALYNNE E 1615 Non-Final OA Jun 07, 2023
18024623 RHO KINASE INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION WARD, PAUL V 1622 Non-Final OA Mar 03, 2023
17766029 A NEW TREATMENT FOR MEIBOMIAN GLAND DYSFUNCTION IVANOVA, SVETLANA M 1627 Non-Final OA Apr 01, 2022
17613467 A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS LEE, WILLIAM Y 1623 Final Rejection Nov 22, 2021
17310235 OLIGONUCLEOTIDES AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION PYLA, EVELYN Y 1633 Final Rejection Jul 27, 2021

Managing The Schepens Eye Research Institute, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month